Abstract
To assess how children with hypertension are currently evaluated and managed, we surveyed 438 North American pediatric nephrologists on how they measure blood pressure (BP), BP goals used in pharmacologically treated patients, and antihypertensive drug choices. 190 replies were received (43% response rate), and 185 were analyzable. Oscillometric and aneroid sphygmomanometers were the most commonly used devices for office BP measurement (74.8% of respondents). Ambulatory blood pressure monitoring was used by 63% of respondents. Goal BP in pharmacologically treated patients was set at the 95th percentile by 39% of respondents, and at the 90th percentile by 59%. Only 37% used a different goal BP in children with hypertension and renal disease; of these, 85% used a lower goal and 15% a higher goal. For hypertensive children with diabetes, 47% used a different goal; 99% lower and 1% higher. Whereas angiotensin-converting enzyme inhibitors (ACEI) and calcium-channel blockers (CCB) were chosen by similar proportions of respondents as initial agents for treatment of primary hypertension, most (84%) chose ACEI as their initial agent for hypertension in children with renal disease.
Although most pediatric nephrologists treat hypertensive children to a BP goal below the 90th percentile, most do not use lower goals for patients with renal disease or diabetes, in contrast with current recommendations for treatment of adults with these conditions. These findings highlight the need for further studies to determine whether recommendations for treatment of hypertension in adults should be followed in children.
Similar content being viewed by others
References
Veterans Administration Cooperative Study Group on Antihypertensive Agents (1967) Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA 202:1028–1034
Veterans Administration Cooperative Study Group on Antihypertensive Agents (1970) Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 213:1143–1152
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289:2560–2572
Bakris GL, Williams M, Dworkin L, Elliot WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J (2000) Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36:646–661
Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland (1987) Report of the second task force on blood pressure control in children—1987. Pediatrics 79:1–25
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (1996) Update on the 1987 task force report on high blood pressure in children and adolescents: a working group report from the national high blood pressure education program. Pediatrics 98:649–658
Sorof JM, Portman RJ (2001) Ambulatory blood pressure measurements. Curr Opin Pediatr 13:133–137
Flynn JT (2001) What’s new in pediatric hypertension? Curr Hypertens Rep 3:503–510
Sakarcan A, Tenney F, Wilson JT, Stewart JJ, Adcock KG, Wells TG, Vachharajani NN, Hadjilambris OW, Slugg P, Ford NF, Marino MR. (2001) The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 41:742–749
Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, Shahinfar S; Enalapril Pediatric Hypertension Collaborative Study Group (2002) A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 42:870–880
Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TJ, Tou C, Kilbaner M (2003) Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 18:548–553
Flynn JT (2003) Successes and shortcomings of the FDA modernization act. Am J Hypertens 16:889–891
O’Brien E (2003) Demise of the mercury sphygmomanometer and the dawning of a new era in blood pressure measurement. Blood Press Monit 8:19–21
Kaufmann MA, Pargger H, Drop LJ (1996) Oscillometric blood pressure measurements by different devices are not interchangeable. Anesth Analg 82:377–381
Butani L, Morgenstern BZ (2003) Are pitfalls of oscillometric blood pressure measurements preventable in children? Pediatr Nephrol 18:313–318
Canzanello VJ, Jensen PL, Schwartz GL (2001) Are aneroid sphygmomanometers accurate in hospital and clinic settings? Arch Intern Med 161:729–731
Lurbe E, Sorof JM, Daniels SR (2004) Clinical and research aspects of ambulatory blood pressure monitoring in children. J Pediatr 144:7–16
Bald M, Hoyer PF (2001) Measurement of blood pressure at home: survey among pediatric nephrologists. Pediatr Nephrol 16:1058–1062
Mansoor GA (2003) A practical approach to persistent elevation of blood pressure in the hypertension clinic. Blood Press Monit 8:97–100
Staessen JA, Den Hond E, Celis H, Fagard R, Keary L, Vandenhoven G, O’Brien ET; Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) Trial Investigators (2004) Antihypertensive treatment based on blood pressure measurement at home or in the physician’s office: a randomized controlled trial. JAMA 291:955–964
Wuhl E, Hadtstein C, Mehls O, Schaefer F; Escape Trial Group (2004) Home, clinic, and ambulatory blood pressure monitoring in children with chronic renal failure. Pediatr Res 55:492–497
Soergel M, Verho M, Wuhl E, Gellermann J, Teichert L, Scharer K (2000) Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension. Pediatr Nephrol 15:113–118
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114(2 Suppl 4th Report):555–576
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Woroniecki, R.P., Flynn, J.T. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol 20, 791–797 (2005). https://doi.org/10.1007/s00467-004-1804-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-004-1804-6